Literature DB >> 17673894

Targeted therapy for metastatic melanoma.

Ravi K Amaravadi1, Keith T Flaherty.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673894

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  5 in total

1.  Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.

Authors:  Xiao-Hong Ma; Shengfu Piao; Dan Wang; Quentin W McAfee; Katherine L Nathanson; Julian J Lum; Lin Z Li; Ravi K Amaravadi
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

2.  Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.

Authors:  Laura M Alwan; Kenneth Grossmann; Daniel Sageser; Joan Van Atta; Neeraj Agarwal; Jeffrey A Gilreath
Journal:  Target Oncol       Date:  2013-04-23       Impact factor: 4.493

3.  Melanoma prevention: are we doing enough? A Canadian perspective.

Authors:  A M Joshua
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

4.  Exploratory use of docetaxel loaded acid-prepared mesoporous spheres for the treatment of malignant melanoma.

Authors:  Sameer Kaiser; Maximilian B MacPherson; Ted A James; Albert Emery; Page Spiess; Albert van der Vliet; Christopher C Landry; Arti Shukla
Journal:  Cancer Nanotechnol       Date:  2015-01-24

5.  Bioelectric applications for treatment of melanoma.

Authors:  Stephen J Beebe; Karl H Schoenbach; Richard Heller
Journal:  Cancers (Basel)       Date:  2010-09-27       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.